Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Pro-Dex, Inc. (NASDAQ:PDEX)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $38.09 and traded as high as $50.06. Pro-Dex shares last traded at $48.98, with a volume of 30,677 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Pro-Dex in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Pro-Dex has an average rating of “Moderate Buy” and an average target price of $56.00.

Pro-Dex Stock Down 0.6%

The company has a debt-to-equity ratio of 0.19, a current ratio of 4.03 and a quick ratio of 2.25. The company has a market capitalization of $157.23 million, a price-to-earnings ratio of 14.41 and a beta of -0.04. The firm has a 50-day moving average price of $43.22 and a two-hundred day moving average price of $38.09.

Pro-Dex (NASDAQ:PDEX) last announced its earnings results on Thursday, January 29th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.07. The business had revenue of $18.66 million for the quarter, compared to analyst estimates of $17.30 million. Pro-Dex had a return on equity of 22.53% and a net margin of 15.73%. As a group, sell-side analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Institutional Trading of Pro-Dex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in shares of Pro-Dex in the fourth quarter worth $220,000. Osaic Holdings Inc. boosted its holdings in Pro-Dex by 44.8% during the fourth quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier’s stock worth $440,000 after purchasing an additional 3,540 shares during the last quarter. Punch & Associates Investment Management Inc. grew its position in Pro-Dex by 23.4% in the fourth quarter. Punch & Associates Investment Management Inc. now owns 60,000 shares of the medical instruments supplier’s stock valued at $2,309,000 after purchasing an additional 11,392 shares in the last quarter. Royal Bank of Canada grew its position in Pro-Dex by 603.4% in the fourth quarter. Royal Bank of Canada now owns 4,080 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 3,500 shares in the last quarter. Finally, First Trust Advisors LP acquired a new stake in Pro-Dex in the 4th quarter valued at $222,000. 15.28% of the stock is currently owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.